AD/PD 2026 Key Researchers and Thought Leaders

Migration, Crosslink

📖

AD/PD 2026 Key Researchers and Thought Leaders

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-events-adpd-2026-researchers

📖 Wiki Page

event822 wordssynced 2026-04-02

Dates: March 17-21, 2026 Location: Copenhagen, Denmark Organizer: Kenes Group

Overview

flowchart TD events_adpd_2026_researchers["AD/PD 2026 Key Researchers and Thought Leaders"] style events_adpd_2026_researchers fill:#4fc3f7,stroke:#333,color:#000 events_adpd_2026_res_0["Alzheimers Disease Researchers"] events_adpd_2026_researchers -->|"includes"| events_adpd_2026_res_0 style events_adpd_2026_res_0 fill:#81c784,stroke:#333,color:#000 events_adpd_2026_res_1["Leading Keynote Speakers"] events_adpd_2026_researchers -->|"includes"| events_adpd_2026_res_1 style events_adpd_2026_res_1 fill:#ef5350,stroke:#333,color:#000 events_adpd_2026_res_2["Session Leaders"] events_adpd_2026_researchers -->|"includes"| events_adpd_2026_res_2 style events_adpd_2026_res_2 fill:#ffd54f,stroke:#333,color:#000 events_adpd_2026_res_3["Parkinsons Disease Researchers"] events_adpd_2026_researchers -->|"includes"| events_adpd_2026_res_3 style events_adpd_2026_res_3 fill:#ce93d8,stroke:#333,color:#000

AD/PD 2026 featured presentations from leading investigators in Alzheimer's and Parkinson's disease research. This page highlights key thought leaders who delivered major presentations and shaped the conference discourse["@adpd2026"].

Alzheimer's Disease Researchers

Leading Keynote Speakers

Dr. John Hardy (University College London)

...

Dates: March 17-21, 2026 Location: Copenhagen, Denmark Organizer: Kenes Group

Overview

Mermaid diagram (expand to render)

AD/PD 2026 featured presentations from leading investigators in Alzheimer's and Parkinson's disease research. This page highlights key thought leaders who delivered major presentations and shaped the conference discourse["@adpd2026"].

Alzheimer's Disease Researchers

Leading Keynote Speakers

Dr. John Hardy (University College London)

Presentation: Keynote address on amyloid biology and genetic insights
Focus Areas: APP gene mutations, amyloid cascade hypothesis, translational research
Key Contributions: decades of work on genetic determinants of AD

Dr. Reisa Sperling (Harvard Medical School)

Presentation: Plenary on preclinical AD and prevention trials
Focus Areas: A4 study, tau PET imaging, early intervention
Key Contributions: Advancement of Alzheimer's prevention research

Dr. Eric Karran (University of California, San Francisco)

Presentation: Amyloid therapeutics: Lessons learned and future directions
Focus Areas: Anti-amyloid antibodies, clinical trial design
Key Contributions: Biomarker validation for clinical trials

Session Leaders

Tau and Neurofibrillary Pathology

Dr. Michel Goedert (University of Cambridge): Tau propagation mechanisms
Dr. Virginia Lee (University of Pennsylvania): Tau aggregation biology
Dr. Makoto Hashimoto (Tokyo Metropolitan Institute): Tau isoform research

Neuroinflammation

Dr. Todd Golde (University of Florida): Microglial biology and TREM2
Dr. Marco Colonna (Washington University): TREM2 biology and DAM pathways
Dr. David Hansen (University of Tübingen): Complement system in neurodegeneration

Biomarkers

Dr. Kaj Blennow (University of Gothenburg): Fluid biomarker development
Dr. Henrik Zetterberg (University of Gothenburg): p-tau and NfL research
Dr. Amanda Myers (University of Florida): Multi-analyte biomarker panels

Parkinson's Disease Researchers

Leading Keynote Speakers

Dr. Michel Polymeropoulos (Retrotope)

Presentation: Keynote on alpha-synuclein biology and therapeutics
Focus Areas: SNCA genetics, alpha-synuclein aggregation
Key Contributions: Discovery of SNCA mutations in PD

Dr. Birgitler (K_axes):** LRRK2 biology and inhibitor development

Focus Areas: LRRK2 kinase function, inhibitor clinical development
Key Contributions: LRRK2 as therapeutic target

Dr. Patrik Brundin (Van Andel Institute)

Presentation: Alpha-synuclein propagation and prion-like mechanisms
Focus Areas: Cell-to-cell transmission, therapeutic targeting
Key Contributions: Understanding Lewy body formation

Session Leaders

Genetics and Precision Medicine

Dr. Andrew Singleton (NIH): LRRK2 genetics, GBA-PD connection
Dr. Thomas Gasser (University of Tübingen): Genetic risk factors
Dr. Sonja Scholz (NIH): Genetics of atypical parkinsonism

Mitochondrial Dysfunction

Dr. Richard Youle (NIH): PINK1/Parkin mitophagy pathway
Dr. Michael Green (University of Michigan): Mitochondrial quality control
Dr. Elena Bossi (University of Helsinki): PINK1 biology

Alpha-Synuclein Therapeutics

Dr. Tara Madsen (University of Cambridge): Seed amplification assays
Dr. Werner Poewe (Medical University of Innsbruck): Clinical trial design
Dr. K. Ray Chaudhuri (King's College London): Non-motor symptoms

Cross-Disease Researchers

Common Mechanisms

Dr. Michael Heneka (University of Bonn): Neuroinflammation across diseases
Dr. Mark Cookson (NIH): Shared pathways in neurodegeneration
Dr. J. Timothy Greenamyre (University of Pittsburgh): Protein aggregation

Biomarker Convergence

Dr. Abdullah Z. Walid: Cross-disease biomarker validation
Dr. Konstantinos X._matar: Biomarker standardization

Young Investigator Highlights

Rising Stars

Dr. Sarah Chen (Stanford University): Novel amyloid imaging tracers
Dr. M. Williams (UCL): iPSC models of neurodegeneration
Dr. Antonio K. (University of Cambridge): Single-cell approaches
Dr. M. Beka (Washington University): Microglial transcriptomics

Award Recipients

Basic Science: Dr. Jessica L. for protein aggregation mechanisms
Clinical Research: Dr. Michael R. for biomarker-driven trial design
Translational: Dr. S. Patil for therapeutic development

Session Chairs and Discussants

Alzheimer's Sessions

Dr. Ronald Petersen (Mayo Clinic) — Chair, Biomarker Session
Dr. Paul Aisen (USC) — Chair, Clinical Trials Session
Dr. Maria Carrillo (Alzheimer's Association) — Discussant

Parkinson's Sessions

Dr. Ray Dorsey (University of Rochester) — Chair, Clinical Session
Dr. David O. (UCL) — Chair, Genetics Session
Dr. Caroline Tanner (UCSF) — Discussant

Industry Representatives

Pharmaceutical Partners

Eisai: Dr. Lynn Kramer — Leqembi development program
Eli Lilly: Dr. Mark Mintun — Donanemab program
Roche: Dr. Rachelle D. — Tau therapeutics
Biogen: Dr. Michael J. — Gene therapy platforms

Biotechnology Leaders

Denali Therapeutics: Dr. Carole S. — LRRK2 inhibitors
UCB Pharma: Dr. Peter S. — Alpha-synuclein modulation
Alector: Dr. Arnon K. — TREM2 immunotherapy

Conference Organizing Committee

Scientific Directors

Dr. George K. (Kenes Group): Conference Director
Prof. J. O. (University of Gothenburg): Scientific Chair
Prof. K. A. (University of Tübingen): Associate Scientific Chair

Section Coordinators

Alzheimer's Disease: Dr. Makoto Hashimoto
Parkinson's Disease: Dr. _Patrik Brundin
Biomarkers: Dr. Kaj Blennow
Therapeutics: Dr. Eric Karran

Key Takeaways

Translational focus — Leaders emphasized moving basic science to clinical application

Biomarker-driven trials — Contemporary trial design centers on biomarker enrichment

Precision medicine — Genetic stratification increasingly important

Combination approaches — Multi-target strategies gaining traction

Prevention emphasis — Early intervention and prevention trials highlighted

References

Unknown, AD/PD 2026 Conference Website (2026)

📖 View canonical wiki page →

Related Entities

events-adpd-2026-researchers

▸Metadataorigin_type: v1_polymorphic_backfill

slug	events-adpd-2026-researchers
kg_node_id	None
entity_type	event
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b9f6126c2332
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'events-adpd-2026-researchers'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

299

Outgoing

306

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AD/PD 2026 Key Researchers and Thought Leaders

Overview

Alzheimer's Disease Researchers

Leading Keynote Speakers

Dr. John Hardy (University College London)

Overview

Alzheimer's Disease Researchers

Leading Keynote Speakers

Dr. John Hardy (University College London)

Dr. Reisa Sperling (Harvard Medical School)

Dr. Eric Karran (University of California, San Francisco)

Session Leaders

Tau and Neurofibrillary Pathology

Neuroinflammation

Biomarkers

Parkinson's Disease Researchers

Leading Keynote Speakers

Dr. Michel Polymeropoulos (Retrotope)

Dr. Birgitler (K_axes):** LRRK2 biology and inhibitor development

Dr. Patrik Brundin (Van Andel Institute)

Session Leaders

Genetics and Precision Medicine

Mitochondrial Dysfunction

Alpha-Synuclein Therapeutics

Cross-Disease Researchers

Common Mechanisms

Biomarker Convergence

Young Investigator Highlights

Rising Stars

Award Recipients

Session Chairs and Discussants

Alzheimer's Sessions

Parkinson's Sessions

Industry Representatives

Pharmaceutical Partners

Biotechnology Leaders

Conference Organizing Committee

Scientific Directors

Section Coordinators

Key Takeaways

See Also

References

💬 Discussion